MA49033A - Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15 - Google Patents
Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15Info
- Publication number
- MA49033A MA49033A MA049033A MA49033A MA49033A MA 49033 A MA49033 A MA 49033A MA 049033 A MA049033 A MA 049033A MA 49033 A MA49033 A MA 49033A MA 49033 A MA49033 A MA 49033A
- Authority
- MA
- Morocco
- Prior art keywords
- immunoconjugates
- mutant
- antibody
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164533 | 2017-04-03 | ||
PCT/EP2018/058034 WO2018184964A1 (fr) | 2017-04-03 | 2018-03-29 | Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49033A true MA49033A (fr) | 2020-02-12 |
MA49033B1 MA49033B1 (fr) | 2022-10-31 |
Family
ID=58488892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49033A MA49033B1 (fr) | 2017-04-03 | 2018-03-29 | Immunoconjugué d'un anticorps contre pd-1 avec il-2 mutée ou avec il-15 |
Country Status (32)
Country | Link |
---|---|
US (2) | US11413331B2 (fr) |
EP (2) | EP4201953A1 (fr) |
JP (3) | JP7426825B2 (fr) |
KR (2) | KR102461885B1 (fr) |
CN (2) | CN117003887A (fr) |
AR (2) | AR111400A1 (fr) |
AU (1) | AU2018247765B2 (fr) |
BR (1) | BR112019017329A2 (fr) |
CA (1) | CA3053357A1 (fr) |
CL (1) | CL2019002346A1 (fr) |
CO (1) | CO2019009354A2 (fr) |
CR (1) | CR20190426A (fr) |
DK (1) | DK3606946T3 (fr) |
ES (1) | ES2928718T3 (fr) |
HR (1) | HRP20221254T1 (fr) |
HU (1) | HUE059885T2 (fr) |
IL (1) | IL269395A (fr) |
LT (1) | LT3606946T (fr) |
MA (1) | MA49033B1 (fr) |
MX (2) | MX2019011770A (fr) |
MY (1) | MY201482A (fr) |
PE (1) | PE20191494A1 (fr) |
PH (1) | PH12019502273A1 (fr) |
PL (1) | PL3606946T3 (fr) |
PT (1) | PT3606946T (fr) |
RS (1) | RS63663B1 (fr) |
RU (1) | RU2761377C2 (fr) |
SG (1) | SG11201909205YA (fr) |
TW (1) | TWI800506B (fr) |
UA (1) | UA125700C2 (fr) |
WO (1) | WO2018184964A1 (fr) |
ZA (1) | ZA201905517B (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
WO2018065938A1 (fr) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Schéma posologique d'avélumab pour le traitement du cancer |
EP3596108A4 (fr) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Immunotolérance ciblée |
CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
EP4201953A1 (fr) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugués d'un anticorps anti-pd-1 avec une il-2 mutante ou avec l'il-15 |
CN110506059B (zh) | 2017-04-05 | 2023-01-17 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
UY37829A (es) | 2017-08-03 | 2019-01-31 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
PE20211270A1 (es) | 2018-01-12 | 2021-07-19 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento |
WO2020060122A1 (fr) | 2018-09-17 | 2020-03-26 | (주)지아이이노베이션 | Protéine de fusion comprenant une protéine il-2 et une protéine cd80 et utilisation associée |
EP3873945A4 (fr) * | 2018-10-29 | 2022-12-28 | 1Globe Biomedical Co., Ltd. | Nouvelles compositions protéiques conçues de manière rationnelle |
KR20210107058A (ko) | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 인간 pd-1에 대항하는 이작용성 분자 |
BR112021012037A2 (pt) * | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula anti-pd-1/il-7 bifuncional |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
CN114786708A (zh) * | 2019-06-05 | 2022-07-22 | 亚设生物治疗公司 | 用于调节免疫细胞功能的突变体白介素-2多肽与抗原结合分子的融合物 |
WO2020259536A1 (fr) * | 2019-06-24 | 2020-12-30 | 南京金斯瑞生物科技有限公司 | Dimère anticorps monoclonal-protéine de fusion de cytokine et son utilisation |
CN116574183A (zh) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
CN112679615B (zh) * | 2019-10-17 | 2023-09-22 | 瑞阳(苏州)生物科技有限公司 | 一种融合蛋白 |
US11692020B2 (en) | 2019-11-20 | 2023-07-04 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
BR112022008129A2 (pt) * | 2019-11-20 | 2022-08-23 | Gi Cell Inc | Composição da cultura de células t reguladoras e uso da mesma |
CA3157575A1 (fr) * | 2019-11-27 | 2021-06-03 | Myoung Ho Jang | Composition de traitement anticancereux, comprenant des cellules nk et une proteine de fusion qui comporte une proteine il-2 et une proteine cd80 |
AU2020403148A1 (en) * | 2019-12-13 | 2022-06-30 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
TW202136317A (zh) | 2019-12-20 | 2021-10-01 | 美商再生元醫藥公司 | 新穎之il2促效劑及其使用方法(二) |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR102559355B1 (ko) * | 2020-01-31 | 2023-07-25 | 주식회사 제넥신 | 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
IL295143A (en) | 2020-02-13 | 2022-09-01 | Hoffmann La Roche | A method for determining the loading state of aav particles using nuclear magnetic resonance relaxometry |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4143329A2 (fr) | 2020-04-28 | 2023-03-08 | Anwita Biosciences, Inc. | Polypeptides d'interleukine-2 et protéines de fusion de ceux-ci, ainsi que leurs compositions pharmaceutiques et leurs applications thérapeutiques |
US20230181712A1 (en) | 2020-05-11 | 2023-06-15 | Hoffmann-La Roche Inc. | Combination therapy with modified pbmcs and an immunoconjugate |
GB2621482A (en) | 2020-05-13 | 2024-02-14 | Bonum Therapeutics Inc | Compositions of protein complexes and methods of use thereof |
CN115916831A (zh) * | 2020-06-30 | 2023-04-04 | Gi 医诺微新 | 包含抗lag-3抗体和il-2的融合蛋白及其用途 |
US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
WO2022098954A1 (fr) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Composés agonistes de tlr et procédés d'immunothérapie anticancéreuse associés |
MX2023006480A (es) * | 2020-12-04 | 2023-06-19 | Hoffmann La Roche | Polipeptidos de interleucina-2 mutante dependientes del ph. |
WO2022125694A1 (fr) * | 2020-12-09 | 2022-06-16 | Asher Biotherapeutics, Inc. | Fusions de polypeptides d'interleukine avec des molécules de liaison à l'antigène bispécifique pour moduler la fonction de cellules immunitaires |
EP4267606A1 (fr) | 2020-12-22 | 2023-11-01 | Neogene Therapeutics B.V. | Marqueurs peptidiques pour suivre des cellules génétiquement modifiées |
CN114712495A (zh) * | 2021-01-06 | 2022-07-08 | 盛禾(中国)生物制药有限公司 | 一种多功能抗体的组合物 |
WO2022148853A1 (fr) * | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugués |
CN117015555A (zh) | 2021-03-09 | 2023-11-07 | 豪夫迈·罗氏有限公司 | Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法 |
CA3209640A1 (fr) | 2021-03-09 | 2022-09-15 | F. Hoffmann-La Roche Ag | Polytherapie d'immunoconjugues variants d'il-2 ciblant pd-1 et de molecules de liaison fap/4-1bb |
JP2024512709A (ja) | 2021-03-30 | 2024-03-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ポリペプチド |
CA3213917A1 (fr) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | Nouvel echafaudage pour molecules bifonctionnelles presentant des proprietes ameliorees |
BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
EP4359428A2 (fr) | 2021-06-23 | 2024-05-01 | Cytune Pharma | Immunocytokines à base d'interleukine-15 |
CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
CN118119635A (zh) * | 2021-09-22 | 2024-05-31 | 信达生物制药(苏州)有限公司 | 白介素2突变体以及其融合蛋白 |
WO2023046156A1 (fr) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Variants d'il-2 et leurs protéines de fusion |
WO2023092006A1 (fr) * | 2021-11-17 | 2023-05-25 | Good Therapeutics, Inc. | Compositions de complexes protéiques et leurs procédés d'utilisation |
TW202342535A (zh) * | 2022-02-11 | 2023-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 免疫綴合物及其用途 |
WO2023245097A2 (fr) | 2022-06-16 | 2023-12-21 | Cephalon Llc | Immunoconjugués anticorps anti-pd1-il2 atténuée et leurs utilisations |
WO2024043643A1 (fr) * | 2022-08-23 | 2024-02-29 | 머스트바이오 주식회사 | Variant d'il2 et complexe protéique le comprenant |
WO2024068705A1 (fr) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Polypeptides activés par une protéase |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1096187A (fr) | 1977-04-18 | 1981-02-24 | Souhei Monden | Traduction non-disponible |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
WO1987000056A1 (fr) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilisation de proteines pour des compositions pharmaceutiques utilisant une conjugaison de polymeres |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993016185A2 (fr) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Proteine de liaison biosynthetique pour marqueur de cancer |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EA003772B1 (ru) | 1996-11-29 | 2003-08-28 | Апплайд Резеч Системз Арс Холдинг Н.В. | Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3 |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
CN1451043A (zh) | 2000-06-29 | 2003-10-22 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
JP2005507870A (ja) | 2001-08-13 | 2005-03-24 | ユニバーシティ・オブ・サザン・カリフォルニア | 低毒性のインターロイキン−2突然変異体 |
CA2466279A1 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
PL206975B1 (pl) | 2001-12-04 | 2010-10-29 | Merck Patent Gmbh | Immunocytokiny o modulowanej selektywności oraz ich zastosowanie |
US7470428B2 (en) | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
WO2004087754A1 (fr) | 2003-04-03 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antagonistes a large spectre efficaces in vivo de la toxine d'un superantigene reposant sur l'interaction entre la molecule cd28 et le superantigene, et utilisations correspondantes |
CA2488441C (fr) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Bibliotheques de phages et anticorps synthetiques |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
HUE025086T2 (en) | 2002-10-10 | 2016-02-29 | Merck Patent Gmbh | Pharmaceutical preparations for ERB-B1 receptor |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
WO2004065416A2 (fr) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Banques de phages anticorps synthetiques |
WO2004072286A1 (fr) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specifique a pd-1 humain |
US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1590372A2 (fr) | 2003-02-06 | 2005-11-02 | Micromet AG | Reponse de lymphocyte t durable |
AU2004217526B2 (en) | 2003-02-28 | 2010-02-04 | St. Jude Children's Research Hospital Inc. | T cell regulation |
ES2388138T3 (es) | 2003-08-27 | 2012-10-09 | Ophthotech Corporation | Terapia de combinación para tratamiento de trastornos neovasculares oculares |
WO2005097832A2 (fr) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Anticorps anti-tgf-$g(b) humanises |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-p-셀렉틴 항체 |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
ES2755976T3 (es) | 2005-02-07 | 2020-04-24 | Roche Glycart Ag | Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
LT2397156T (lt) | 2005-06-08 | 2017-02-27 | Dana-Farber Cancer Institute, Inc. | Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią |
JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
WO2007062466A1 (fr) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demi-corps : agents thérapeutiques activés par dimérisation |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
WO2007134050A2 (fr) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Polypeptides de liaison à squelettes optimisés |
RU2487888C2 (ru) | 2006-06-12 | 2013-07-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Одноцепочечные мультивалентные связывающие белки с эффекторной функцией |
BRPI0713000A8 (pt) | 2006-06-12 | 2017-12-05 | Trubion Pharmaceuticals Inc | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples |
EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
DK2066796T3 (da) | 2006-09-20 | 2011-10-03 | Mt Biomethan Gmbh | Fremgangsmåde og indretning til fraskillelse af methan og kuldioxid fra biogas |
EP2102241A2 (fr) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Séquences d'acides aminés qui modulent l'interaction entre des cellules du système immunitaire |
CA2947292C (fr) | 2006-12-27 | 2019-07-23 | Emory University | Compositions et procedes pour le traitement d'infections et de tumeurs |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009015917A2 (fr) | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Inhibiteurs dihydroquinone et dihydronaphtridine de jnk |
EP2169404B1 (fr) | 2007-06-18 | 2016-01-27 | Chugai Seiyaku Kabushiki Kaisha | PROCÉDÉ DE MESURE DE L'ACTIVITÉ DE LIAISON D'UN ANTICORPS AVEC UN ANTIGÈNE ET AVEC UN RÉCEPTEUR Fc |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
WO2009014708A2 (fr) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation |
WO2009024531A1 (fr) | 2007-08-17 | 2009-02-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de traitement et de diagnostic de malignités hématologiques |
CA2703947C (fr) | 2007-10-26 | 2018-12-04 | Governing Council Of The University Of Toronto | Methodes therapeutiques et diagnostiques utilisant le tim-3 |
WO2009061853A2 (fr) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Polypeptides d'interleukine-2 (il-2) mutants |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
EP2242773B1 (fr) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Anticorps monoclonaux pour le traitement de tumeurs |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
EP3103875A1 (fr) | 2008-07-21 | 2016-12-14 | Apogenix AG | Molécules à chaîne unique tnfsf |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2350129B1 (fr) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
US9598491B2 (en) | 2008-11-28 | 2017-03-21 | Emory University | Methods for the treatment of infections and tumors |
JP5569946B2 (ja) | 2009-01-26 | 2014-08-13 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
US20110313129A1 (en) | 2009-02-11 | 2011-12-22 | Life Technologies Corporation | Large stokes shift dyes |
PE20120591A1 (es) | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
CN102573922B (zh) | 2009-08-17 | 2015-08-05 | 罗切格利卡特公司 | 靶向性免疫缀合物 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
DK2519543T3 (en) | 2009-12-29 | 2016-09-26 | Emergent Product Dev Seattle | HETERODIMER BINDING PROTEINS AND USE THEREOF |
ES2638521T5 (es) * | 2010-03-05 | 2021-03-02 | Univ Johns Hopkins | Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
WO2011143545A1 (fr) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Protéines hétérodimériques et leurs procédés de production et de purification |
PT2581113T (pt) | 2010-06-11 | 2018-07-04 | Univ Kyushu Nat Univ Corp | Anticorpo anti-tim-3 |
WO2011159877A2 (fr) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques |
NO2603530T3 (fr) | 2010-08-13 | 2018-04-07 | ||
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
ES2694564T3 (es) * | 2011-02-10 | 2018-12-21 | Roche Glycart Ag | Polipéptidos de interleucina-2 mutantes |
EP2691417B1 (fr) | 2011-03-29 | 2018-08-01 | Roche Glycart AG | Variants de fc d'anticorps |
EP2694550B1 (fr) | 2011-04-01 | 2019-11-27 | Universität Stuttgart | Polypeptides recombinés membres de la famille des ligands tnf ayant un domaine de liaison d'un anticorps et leurs utilisations |
JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | B7−h1およびpd−1に結合する抗体およびその他の分子 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2013006490A2 (fr) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Anticorps se liant spécifiquement à tim3 |
FR2977674B1 (fr) | 2011-07-06 | 2015-08-14 | Cisbio Bioassays | Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule |
EP2543680A1 (fr) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Fragment Fab d'anticorps multi-spécifiques mutés |
LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
SG2014012298A (en) | 2011-08-11 | 2014-06-27 | Medarex Llc | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
FR2980271B1 (fr) | 2011-09-16 | 2013-10-11 | Cisbio Bioassays | Procede de determination de la glycosylation d'un anticorps |
SI2794905T1 (sl) | 2011-12-20 | 2020-08-31 | Medimmune, Llc | Modificirani polipeptidi za ogrodja bispecifičnega protitelesa |
CN106443016B (zh) | 2012-02-01 | 2019-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
CA2860600C (fr) | 2012-02-15 | 2022-07-26 | F. Hoffmann-La Roche Ag | Chromatographie d'affinite faisant appel a des recepteurs fc |
WO2013141372A1 (fr) | 2012-03-22 | 2013-09-26 | 三井造船株式会社 | Dispositif de mesure de fret et procédé de mesure de transfert d'énergie par résonance de fluorescence |
MX360110B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
MY174248A (en) | 2012-04-30 | 2020-04-01 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
EP3495387B1 (fr) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires |
ES2700978T3 (es) * | 2012-08-07 | 2019-02-20 | Roche Glycart Ag | Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada |
EP2904093B1 (fr) | 2012-10-03 | 2019-04-10 | Zymeworks Inc. | Procédés de quantification de paires polypeptidiques de chaînes lourdes et légères |
ME03796B (fr) | 2013-03-15 | 2021-04-20 | Glaxosmithkline Ip Dev Ltd | Protéines de liaison anti-lag-3 |
CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
AU2014304931B2 (en) * | 2013-08-08 | 2018-05-10 | Assistance Publique - Hopitaux De Paris | IL-15 and IL-15Raplha sushi domain based modulokines |
KR20230008255A (ko) | 2013-09-20 | 2023-01-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
EP3757130A1 (fr) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
CA2934028A1 (fr) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Polytherapie comprenant des agonistes se liant a ox40 et des antagonistes se liant a l'axe pd-1 |
JP6786392B2 (ja) | 2014-01-15 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合特性が改変され、プロテインA結合特性が保持されているFc領域変異体 |
US10794898B2 (en) | 2014-01-17 | 2020-10-06 | Regents Of The University Of Minnesota | High-throughput, high-precision methods for detecting protein structural changes in living cells |
TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
PT3556775T (pt) | 2014-01-28 | 2021-12-31 | Bristol Myers Squibb Co | Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas |
HUE048531T2 (hu) | 2014-03-14 | 2020-07-28 | Novartis Ag | Antitest molekulák a LAG-3-hoz és ezek felhasználása |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
AU2015249633B2 (en) | 2014-04-25 | 2020-10-15 | Genentech, Inc. | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
CN106794245B (zh) * | 2014-08-29 | 2021-06-01 | 豪夫迈·罗氏有限公司 | 肿瘤靶向性il-2变体免疫细胞因子和针对人pd-l1的抗体的组合疗法 |
KR102011205B1 (ko) | 2014-11-06 | 2019-08-14 | 에프. 호프만-라 로슈 아게 | 항-tim3 항체 및 사용 방법 |
HUE054122T2 (hu) | 2014-11-14 | 2021-08-30 | Hoffmann La Roche | TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák |
ES2835823T3 (es) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
ES2881484T3 (es) | 2014-12-22 | 2021-11-29 | Pd 1 Acquisition Group Llc | Anticuerpos anti-PD-1 |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
EP3064507A1 (fr) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Protéines de fusion comprenant une protéine de liaison et un polypeptide interleukine-15 ayant une affinité réduite pour IL15ra et leurs utilisations thérapeutiques |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2016210129A1 (fr) | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Nouveaux agents de modulation immunitaire pd -1 |
CN108348601B (zh) | 2015-07-22 | 2022-05-17 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
SG10201913864RA (en) | 2015-09-02 | 2020-03-30 | Immutep Sas | Anti-LAG-3 Antibodies |
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
JP6734919B2 (ja) | 2015-10-02 | 2020-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 同時結合を測定するための細胞ベースのfretアッセイ法 |
HRP20211594T1 (hr) | 2015-10-02 | 2022-01-21 | F. Hoffmann - La Roche Ag | Anti-pd1 protutijela i načini uporabe |
MY193013A (en) | 2015-10-07 | 2022-09-22 | Hoffmann La Roche | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
EP3370759A1 (fr) | 2015-11-03 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Polythérapie au moyen d'un inhibiteur d'ensemble capside hbv et d'un interféron |
US10858432B2 (en) | 2015-12-02 | 2020-12-08 | Stcube, Inc. | Antibodies specific to glycosylated PD-1 and methods of use thereof |
WO2017097728A1 (fr) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Dérivés de pipéridine pontés |
CN109071636A (zh) | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
EP3243836A1 (fr) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c |
EP3455254B1 (fr) | 2016-05-11 | 2021-07-07 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison de ténascine |
EP3243832A1 (fr) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1 |
CN106519034B (zh) * | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
EP4201953A1 (fr) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugués d'un anticorps anti-pd-1 avec une il-2 mutante ou avec l'il-15 |
EP3606947B1 (fr) | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugué de il-2 avec un anticorps bispécifique contre pd-1 et tim-3 |
EA201992350A1 (ru) | 2017-04-05 | 2020-03-23 | Симфоген А/С | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 |
CN110506059B (zh) | 2017-04-05 | 2023-01-17 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
EP3606556A1 (fr) | 2017-04-05 | 2020-02-12 | Boehringer Ingelheim International GmbH | Polythérapie anticancéreuse |
AU2018247797A1 (en) | 2017-04-05 | 2019-08-22 | F. Hoffmann-La Roche Ag | Anti-LAG3 antibodies |
-
2018
- 2018-03-29 EP EP22191366.8A patent/EP4201953A1/fr not_active Withdrawn
- 2018-03-29 CN CN202310831443.4A patent/CN117003887A/zh active Pending
- 2018-03-29 SG SG11201909205Y patent/SG11201909205YA/en unknown
- 2018-03-29 PL PL18715008.1T patent/PL3606946T3/pl unknown
- 2018-03-29 MY MYPI2019005796A patent/MY201482A/en unknown
- 2018-03-29 HU HUE18715008A patent/HUE059885T2/hu unknown
- 2018-03-29 JP JP2019554375A patent/JP7426825B2/ja active Active
- 2018-03-29 WO PCT/EP2018/058034 patent/WO2018184964A1/fr unknown
- 2018-03-29 LT LTEPPCT/EP2018/058034T patent/LT3606946T/lt unknown
- 2018-03-29 ES ES18715008T patent/ES2928718T3/es active Active
- 2018-03-29 KR KR1020217031434A patent/KR102461885B1/ko active IP Right Grant
- 2018-03-29 CA CA3053357A patent/CA3053357A1/fr active Pending
- 2018-03-29 CN CN201880017251.7A patent/CN110392692B/zh active Active
- 2018-03-29 UA UAA201910599A patent/UA125700C2/uk unknown
- 2018-03-29 DK DK18715008.1T patent/DK3606946T3/da active
- 2018-03-29 PT PT187150081T patent/PT3606946T/pt unknown
- 2018-03-29 RU RU2019134338A patent/RU2761377C2/ru active
- 2018-03-29 MX MX2019011770A patent/MX2019011770A/es unknown
- 2018-03-29 KR KR1020197027871A patent/KR20190121816A/ko not_active IP Right Cessation
- 2018-03-29 MA MA49033A patent/MA49033B1/fr unknown
- 2018-03-29 BR BR112019017329A patent/BR112019017329A2/pt unknown
- 2018-03-29 EP EP18715008.1A patent/EP3606946B1/fr active Active
- 2018-03-29 CR CR20190426A patent/CR20190426A/es unknown
- 2018-03-29 AU AU2018247765A patent/AU2018247765B2/en active Active
- 2018-03-29 HR HRP20221254TT patent/HRP20221254T1/hr unknown
- 2018-03-29 PE PE2019001547A patent/PE20191494A1/es unknown
- 2018-03-29 RS RS20220957A patent/RS63663B1/sr unknown
- 2018-04-02 US US15/943,237 patent/US11413331B2/en active Active
- 2018-04-02 TW TW107111572A patent/TWI800506B/zh active
- 2018-04-03 AR ARP180100833A patent/AR111400A1/es unknown
-
2019
- 2019-08-20 CL CL2019002346A patent/CL2019002346A1/es unknown
- 2019-08-21 ZA ZA2019/05517A patent/ZA201905517B/en unknown
- 2019-08-28 CO CONC2019/0009354A patent/CO2019009354A2/es unknown
- 2019-09-16 IL IL26939519A patent/IL269395A/en unknown
- 2019-09-30 MX MX2023003397A patent/MX2023003397A/es unknown
- 2019-10-02 PH PH12019502273A patent/PH12019502273A1/en unknown
-
2022
- 2022-01-05 JP JP2022000421A patent/JP2022062001A/ja not_active Withdrawn
- 2022-06-30 US US17/810,041 patent/US20230134606A1/en active Pending
- 2022-09-06 AR ARP220102406A patent/AR126987A2/es unknown
-
2023
- 2023-12-27 JP JP2023221984A patent/JP2024045143A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49033A (fr) | Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15 | |
MA49043A (fr) | Formulation stable d'anticorps | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
MA43956A (fr) | Constructions d'anticorps bispécifiques d'engagement avec les cellules t | |
MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
MA53434A (fr) | Anticorps anti-tigit | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
TWD200284S (zh) | 口腔保健用具 | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
MA49749A (fr) | Anticorps anti-cd137 | |
MA54052A (fr) | Formulation d'anticorps | |
MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
TWD196690S (zh) | 口腔保健用具 | |
MA45450B1 (fr) | Formulations d'anticorps anti-cd19 | |
MA54139A (fr) | Formulation d'anticorps | |
MA52152A (fr) | Anticorps | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
MA46721A (fr) | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
MA51147A (fr) | Associations d'anticorps anti-c5 et utilisations associées |